Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Molina Healthcare plunges after surprise Q4 loss

(Sharecast News) - Shares in Molina Healthcare plunged on Friday after the US managed care group reported an unexpected fourth-quarter loss and issued sharply weaker-than-expected guidance for 2026, triggering a sell-off that drove the stock to a near six-year low. Molina posted an adjusted loss of $2.75 per share for the fourth quarter, compared with market expectations for a profit of 34 cents, as medical costs surged across its Medicaid, Medicare Advantage and Affordable Care Act Marketplace businesses.

Revenue rose 8.3% year-on-year to $11.38bn, beating forecasts, but profitability was hit by roughly $2 per share in adverse retroactive premium adjustments linked to its California Medicaid operations.

The group's consolidated medical care ratio deteriorated to 94.6% from 90.2% a year earlier.

Cost pressures were particularly acute in Molina's Marketplace and Medicare Advantage segments, where medical loss ratios climbed well above expectations, reflecting higher utilisation and weaker risk pools.

Management also flagged a steep contraction in Affordable Care Act Marketplace membership, forecasting a fall to about 220,000 members by the end of 2026 from more than 700,000 in late 2025, as the company exits counties, raises premiums and grapples with the expiry of enhanced federal subsidies.

The outlook for 2026 further unsettled investors.

Molina forecast adjusted earnings of at least $5.00 per share on revenue of at least $44.5bn, far below analyst expectations.

The company said guidance incorporates around $2.50 per share of headwinds, including costs associated with a new Florida Medicaid contract and ongoing losses in traditional Medicare Advantage Part D plans, which it intended to exit in 2027.

Chief executive Joseph Zubretsky described 2026 as a potential "trough year" for Medicaid margins as rates lag underlying cost trends.

Analysts reacted cautiously - Bank of America reiterated an underperform rating, citing limited visibility on Medicaid and exchange risk pools, while Jefferies questioned whether Medicaid margins would stabilise as quickly as management expects.

At 1218 ET (1718 GMT), shares in Molina Healthcare were down 27.92% at $127.50.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

Next 15 first-half results in line as profits, revenue dip
(Sharecast News) - Shares of Next 15 slid on Thursday after it reported a dip in first-half profit and revenue, albeit in line with expectations.
Samsung Electronics guides to huge surge in Q3 profits
(Sharecast News) - Samsung Electronics on Thursday guided to a near-ninefold increase in operating profits in the third quarter, with the predicted quarterly total more than double what the memory chipmaker earned in 2025 - though numbers still came up short of analysts' projections.
Friday preview: Delta Air Lines results in focus
(Sharecast News) - Friday sees the release of quarterly results from Delta Air Lines in the US, along with the preliminary Michigan consumer sentiment index for October.
Asos hackers accessed more customer details than first thought
(Sharecast News) - More customer information than first thought was accessed in the Asos cyber attack that came to light earlier this week, after hackers gained access to an employee account by impersonating a trusted contact.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.